with zidovudine plus single-dose nevirapine, for
the prevention of mother-to-child transmission
in HIV-infected women with high CD4 cell counts
but also showed higher rates of adverse events.
On the basis of recent trials, the WHO recommends ART for HIV-infected persons regardless
of CD4 cell count, and there are clear benefits of
ART for the prevention of mother-to-child transmission and maternal health.26,27 However, it is
also clear that the most efficacious and safest
triple-drug ART regimens during pregnancy remain to be defined. Our findings emphasize the
need for continued research to assess ART in
pregnancy to ensure safer pregnancies for HIVinfected women and healthier outcomes for their
uninfected infants.